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Our recently published data demonstrate significant similarities between normal and malignant plasma cells in the
cellular and molecular interactions that support their survival in the bone marrow microenvironment, and suggest that
the biology of multiple myeloma may largely reflect that of their normal counterparts.
Introduction
Multiple myeloma (MM) is a clonal
neoplasm of the normal bone marrow-
resident long lived plasma cells. Like
normal plasma cells, MM depend on their
interactions with bone marrow stromal
cells (BMSC) for survival and production
of essential growth factors.
1 But it remains
largely unclear which specific stromal cell
types or molecules are involved in these
interactions. Our recent studies have
shown that activation of CD28, a pro-
totypical co-stimulatory molecule on T-
cells, (overexpression of which is a poor
prognostic marker in myeloma patients)
2
protects myeloma cells against apoptosis in
vitro.
3 Antigen presenting cells (APC) such
as dendritic cells (DC) and other myeloid
cells that provide the ligands CD80/CD86
for CD28 activation on T-cells are also
found to be closely associated with
myeloma cells in the BM. Our recently
published work
4 extend these observations
and define similarities in the role for
CD28 and DC in supporting normal PC
as well as myeloma by inducing pro-
survival signals and modulating the
BM microenvironment in vitro and in
vivo.
5
Dendritic Cells Support Myeloma
and Plasma Cell Survival
Our findings
4 that BM from MM patients
have a higher percentage of CD11b
+
myeloid cells compared with normal
controls, and that myeloid DC protect
MM in vitro against cell death
3 and that
DC produce both IL-6 (an essential MM
cytokine
6) as well as the immunosuppres-
sive enzyme indoleamine 2,3 dioxygenase
[IDO,
7 induces anergy in activated T-cells
by depleting the essential amino acid
tryptophan or induce them to become T-
regs (known to accumulate in the BM of
MM patients)
8] in co-cultures with MM;
all suggest that DC have the potential to
modulate the BM microenvironment.
Expanding on recent studies on the role
of DC in B-cell and PC survival,
9 our
work
5 demonstrates that direct interactions
between DC and PC in murine BM is
important for their long-term survival and
function. Despite the complexity of the
PC-DC cellular interaction, PC survival,
Ig production and induction of DC IL-6
production were completely dependent on
the interaction between CD28 on the
MM/PC and CD80/CD86 on the stromal
DC.
CD28: A Cell Intrinsic Survival
Receptor for Normal and Malignant
Plasma Cells
CD28 activation by antibodies or by co-
culture with CD80/CD86
+ DC protected
both myeloma cells
4 and normal BM
plasma cells
5 from death induced by serum
starvation or chemotherapeutic agents in
vitro and this was abrogated when agents
that block CD80/CD86 or CD28 were
included in the co-cultures. Similar to
myeloma, loss of CD28 specifically in the
B-cell lineage significantly reduced normal
BM PC survival and prevented the
generation of long-term antigen specific
antibody titers.
5 These findings support a
central role for CD28 function in the
maintenance of normal PC survival within
BM and show that CD28 plays a key pro-
survival role for normal BM resident
plasma cells and multiple myeloma cells.
Similar to T-cell models,
7,10 not only does
blocking CD28 in MM-DC co-cultures
abrogate the protective effect of DC on MM
survival, but also reduces DC ability to
produce IL-6 or IDO thus suggesting that
CD28 might be amolecular bridge by which
MM/PC modulate the microenvironment.
Moreover, IDO activity in these co-cultures
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www.landesbioscience.com OncoImmunology 387was sufficient to induce activated T-cells to
become T-regs and could play a potential
role in suppressing anti-myeloma T-cell
responses in patients (T-regs are known to
accumulate in the BM of MM patients
8).
IDO may also create a nutritionally-depleted
niche within the highly proliferative BM
that is more favorable for the survival of
myeloma cells, which have a lower prolif-
erative index and are less susceptible to
tryptophan depletion. Based on these find-
ings, a model of DC and CD28 interactions
in the MM pro-survival niche is proposed in
Figure1. Newly differentiated normal PC or
myeloma cells from germinal centers in the
lymph node (1) traffic to the BM via
CXCR4 expressed by MM/PC and
CXCL12 expressed by BMSC (2), where
they interact with myeloid dendritic cells
(DC) through CD28 on MM/PC and
CD80/CD86 on DC. Ligation of CD28
delivers pro-survival signals to the MM/PC
and simultaneously, ligation of CD80/
CD86 induces the DC to make IL-6 and
IDO (3). While the IL-6 promotes survival
in MM/PC, IDO depletes the essential
amino acid tryptophan by converting it into
its metabolite L-kynurenine. This directly
suppresses T cell activation and also induces
the generation of T-regs (4), and both
contribute to the immunosuppressive envir-
onment characteristic of multiple myeloma.
Blocking the CD28-CD80/CD86 inter-
action (5) with agents such as CTLA4-Ig
or CD28(Fab) downregulates IL-6 and IDO
production, and also blocks DC-mediated
survival in myeloma cells.
Just like in MM, we also found that
CD28-CD80/CD86 interactions are crit-
ical for the in vivo survival of normal
BM PC and production of antibody titers
in murine models and induced DC
production of IL-6 in co-cultures, which
was completely (CD80) or largely (CD86)
lost when CD80 or CD86 were blocked.
5
Significantly diminished antigen-specific
antibody titers following vaccination in
CD80
2/2 or CD86
2/2 mice compared
with fewer BM resident PC suggest that
CD28 expressed on PC and their inter-
action with CD80/CD86 play an essential
role in the survival of normal PC just like
that observed in myeloma.
Targeting the myeloma microenviron-
ment offers a rational direction toward
developing novel anti-myeloma drugs.
Studies by others
9 and by us
4,5 show
common elements in the pro-survival
niches of both normal PC and MM,
indicating that therapeutics developed to
target PC in autoimmune diseases or organ
graft rejection may have significant efficacy
in the treatment of multiple myeloma.
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Figure1. Model of the microenvironment niche interactions for plasma cells/myeloma cells in the bone marrow.
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